Full text is available at the source.
Abstract
Individuals with schizophrenia spectrum disorders face significant metabolic abnormalities linked to their treatment.
- Metabolic abnormalities are prevalent in individuals with schizophrenia spectrum disorders.
- Antipsychotic treatment may worsen these metabolic issues.
- Increased cardiovascular problems and early death are associated with these metabolic conditions.
- GLP-1 receptor agonists have shown metabolic benefits in the general population.
- The effectiveness and safety of GLP-1 receptor agonists for those with schizophrenia are not yet established.
Simplified